Hefter, H.; Schomaecker, I.; Schomaecker, M.; Rosenthal, D.; Samadzadeh, S.
The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study. Medicina 2022, 58, 88.
https://doi.org/10.3390/medicina58010088
AMA Style
Hefter H, Schomaecker I, Schomaecker M, Rosenthal D, Samadzadeh S.
The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study. Medicina. 2022; 58(1):88.
https://doi.org/10.3390/medicina58010088
Chicago/Turabian Style
Hefter, Harald, Isabelle Schomaecker, Max Schomaecker, Dietmar Rosenthal, and Sara Samadzadeh.
2022. "The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study" Medicina 58, no. 1: 88.
https://doi.org/10.3390/medicina58010088
APA Style
Hefter, H., Schomaecker, I., Schomaecker, M., Rosenthal, D., & Samadzadeh, S.
(2022). The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study. Medicina, 58(1), 88.
https://doi.org/10.3390/medicina58010088
